Housekeeping

• To avoid background noise all participants will be muted.
• After testing your speakers, please do remember to connect your audio by using the “Join Audio” icon at the bottom left of the screen or dial in via phone using the number provided in the joining instructions.
• If you have any technical problems, please use the chat to seek advice from the host (Andie McLean)
• Questions and Answers: Use the Q&A function. We will pick them up at 10:45 “Q&A session”.
• Please use the chat to introduce yourself, please note due to GDPR we cannot share the chat. Capture what you need.
## AGENDA

<table>
<thead>
<tr>
<th>Time (UK)</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Welcome &amp; Innovate UK KTN European Programmes support</td>
<td>Belen Rebollo, Innovate UK KTN</td>
</tr>
<tr>
<td>10:05</td>
<td>Horizon Europe Health Cluster and NCP support</td>
<td>Tristan Fancourt, UKRI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jo Frost, Innovate UK</td>
</tr>
<tr>
<td>10:25</td>
<td>Innovative Health Initiative Programme</td>
<td>Elisabetta Vaudano, IHI</td>
</tr>
<tr>
<td>10:35</td>
<td>JPI AMR (Antimicrobial Resistance) Programme</td>
<td>Laura Marin, JPI AMR</td>
</tr>
<tr>
<td>10:40</td>
<td>European Innovation Council (EIC) – Health highlights</td>
<td>Claire Griffin, Innovate UK</td>
</tr>
<tr>
<td>10:50</td>
<td>Research Infrastructures Work Programme</td>
<td>Alice Chadwick, UKRI</td>
</tr>
<tr>
<td>10:55</td>
<td>Other Health opportunities</td>
<td>Jo Frost, Innovate UK</td>
</tr>
<tr>
<td>11:00</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>Case Study - Cell and Gene Therapy Catapult</td>
<td>Sharon Brownlow, Catapult</td>
</tr>
<tr>
<td>11:30</td>
<td>Navigating application and award process: Practical tips and</td>
<td>Chris Young, Innovate UK</td>
</tr>
<tr>
<td></td>
<td>support for applicants</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>11:50</td>
<td>Close / Next steps</td>
<td>Belen Rebollo, Innovate UK KTN</td>
</tr>
</tbody>
</table>
Innovate UK KTN exists to connect innovators with new partners and new opportunities beyond their existing thinking – accelerating ambitious ideas into real-world solutions.

Cross-Sector Expertise

Agrifood
Biotechnology
Chemistry
Creative Industries
Design
Digital
Electronics
Energy
Geospatial
Health
Industrial Maths
Infrastructure

Manufacturing
Materials
Photonics
Quantum
Robotics & AI
Security & Defence
Sensors
Space
Transport
Water
Our Network

- 46,229 Unique Organisations
- 72% Small
- 15% Medium
- 13% Large
- Every university in the UK

Our Outputs

- 66% introduced by KTN go on to collaborate
- 42% reach outcomes faster (1-2 years)
- 60% increased investment in R&D direct result from KTN engagement
- £100m per year increased investment in R&D
Primary Delivery Partners

UK Government
Building the future economy
Plan for action for UK business innovation

Theme 3: Global opportunities

More and more countries are looking to science and innovation to build their economies and meet global challenges. There is a major opportunity for international co-operation on research and development and innovation that builds on our world-class science and research capabilities and industry strengths.
We connect **regional, national and global** innovation

Our **Global Alliance** programme drives international collaborations with governments, societies, enterprises, institutions and people from every corner of the globe.
Our Reach
We support UK organisations in **engaging with International R&I initiatives** (i.e. Horizon Europe and EUREKA, among them) and help shape future funding priorities by:

- Organising consortium building activities / events in selected topics
- Offering “Travel Grants” to attend European brokerage events
- Managing international collaboration platforms
- Engaging with International Partnerships and Technology Platforms
- Providing sector specific advice on market opportunities and project impact

*We work closely with the National Contact Points, Innovate UK Edge and the FCDO / Science Innovation Network.*
Global Alliance: European Programmes

European Programmes Experts

Jane Watkins
Regional Lead

Viola Hay
Knowledge Transfer Manager

Belen Rebollo
Knowledge Transfer Manager

Find out more

@KTN_Global
Horizon Europe Hub
https://ktn-uk.org/programme/european
Horizon Europe Cluster 1

Tristan Fancourt
NCP Health

Jo Frost
NCP Health
Horizon Europe Health Cluster
2023-2024 Funding Calls
Including Partnerships and Cancer Mission
2 Dec 2022

UK National Contact Points for Horizon Europe Health:
Tristan Fancourt - contact for academia (ncp@mrc.ukri.org)
Jo Frost - contact for industry (ncp-health@iuk.ukri.org)

If you are from another sector (e.g. Charity, Government, NHS) please copy both Jo and Tristan into your email
What is a National Contact Point (NCP)?

**UK NCP network:** Team of sector specific public servants whose role it is to provide free support to UK participants to Horizon Europe

**International NCP network:** support in Europe and the rest of the World

NCP services vary in each country/sector, but typically include:

- **Informing, awareness raising** – on Horizon Europe and other EU programmes
- **Assisting, advising and training** – to improve the quality of Horizon Europe proposals
- **Signposting and cooperation** – direct to relevant support and work with each other to support consortium development

Sign up to the UK NCP newsletters for the latest Horizon Europe health funding opportunities news
Horizon Europe Structure

**Pillar I**
**EXCELLENT SCIENCE**
- European Research Council
- Marie Skłodowska-Curie
- Research Infrastructures

**Pillar II**
**GLOBAL CHALLENGES & EUROPEAN INDUSTRIAL COMPETITIVENESS**
- **Health**
- Culture, Creativity & Inclusive Society
- Civil Security for Society
- Digital, Industry & Space
- Climate, Energy & Mobility
- Food, Bioeconomy, Natural Resources, Agriculture & Environment

**Clusters**
- Joint Research Centre**

**Pillar III**
**INNOVATIVE EUROPE**
- European Innovation Council
- European innovation ecosystems
- European Institute of Innovation & Technology*

**WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA**
- Widening participation & spreading excellence
- Reforming & Enhancing the European R&I system

€53.8bn
€24.9bn
€13.4bn
Health Cluster 2023-2024 Work Programme

- **Draft Health Work Programme (Cluster 1) for 2023-2024**

- **~ €1.1 billion funding available** (excluding partnerships)

- Divided into six ‘destinations’ (research themes) each containing a number of call topics (funding opportunities)

- **Deadlines (tbc):** 13 April 2023, 19 Sept 2023 or 11 April 2024 dependent on topic
Types of Countries in Horizon Europe

**List of Participating Countries in Horizon Europe** contains information about countries eligible for funding.

- **EU Member States** and their overseas territories
- **Associated Countries**
- **Third Countries**: Most Low and Middle Income Countries (except for BRIC, Mexico, Chile, etc.)
- **Third countries**: Developing economies (BRIC, Mexico, Chile…) and industrialised countries (Canada, Japan, US*)

The Swiss government will fund Swiss organisations to take part in Horizon Europe consortia: [https://www.horizon-europe.ch](https://www.horizon-europe.ch)

**Automatically eligible to receive EU funding**

- Can participate with own funding.
- Only funded by Commission in exceptional cases

*However, US organisations are eligible for funding in Cluster 1 Health (only)*
Consortia Size

Minimum consortium size

- **Collaborative projects** (Research and Innovation Actions, Innovation Actions)
  Usually a consortium must have a minimum of 3 independent legal entities, each established in different EU Member States (MS) or Associated Countries (AC), with at least 1 of them established in a MS

- In reality consortia are normally larger than this:

  Societal Challenge 1 on “Health; Demographic Change and Well-being” of the previous EU R&I programme, Horizon 2020 (2014-2020):

  - 80% of RIAs had between 7 to 18 participants (13 in average)
  - 613 projects (RIAs) involving 8143 participants:
    - from EU Member States (87%), H2020 Associated Countries (7%)
    - other Third Countries (6%)
  - Type of organisations: Higher or Secondary Education Establishments (42%), Private for-profit entities (23%), Research Organisations (23%), Public bodies (6%), Other (6%).

  \textit{RIA = Research and Innovation Action, which is the most common project type}
UK Success in Horizon Europe Health Cluster

2021 Health Calls

• ~105 successful participations (~8% of total successful participations for all countries)

• ~ €61 million to UK proposals on ‘main list’ (~8% of total budget for all countries)

2021 & 2022 Health Calls*

• 22% success rate for proposals with UK participants (higher than 18% success rate across all proposals)

* Data source: Horizon Europe Dashboard – R&I proposals section as at 29/11/22
Health Cluster - Destination 1

Info based on DRAFT Cluster 1 Work Programme (published 29/11/22)

Staying healthy in a rapidly changing society

€120m
10 projects funded

2023 Call (Single Stage)
(Deadline 13 April 2023 tbc)

The Silver Deal – Person-centred health and care in European regions

2024 Call (Two Stage)
(First Stage Deadline 19 Sept 2023 tbc)

Towards a holistic support to children and adolescents' health and care provisions in an increasingly digital society

Personalised prevention of non-communicable diseases - addressing areas of unmet needs using multiple data sources
## Living and working in a health-promoting environment

**2023 Call (Single Stage)**
*(Deadline 13 April 2023 tbc)*

- Planetary health: understanding the links between environmental degradation and health impacts
- Evidence-based interventions for promotion of mental and physical health in changing working environments (post-pandemic workplaces)
- Health impacts of endocrine-disrupting chemicals: bridging science-policy gaps by addressing persistent scientific uncertainties
- Global coordination of exposome research

**2024 Call (Two Stage)**
*(First Stage Deadline 19 Sept 2023 tbc)*

The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution

26 projects funded

Info based on DRAFT Cluster 1 Work Programme (published 29/11/22)
Health Cluster - Destination 3

Info based on DRAFT Cluster 1 Work Programme (published 29/11/22)

**63 projects funded**

**Tackling diseases and reducing disease burden***

**2023 Call (Single Stage)**
(Deadline 13 April 2023 tbc)

- Novel approaches for palliative and end-of-life care for non-cancer patients
- Interventions in city environments to reduce risk of non-communicable disease (Global Alliance for Chronic Diseases - GACD)
- Towards structuring brain health research in Europe
- Relationship between infections & non-communicable diseases

**Pandemic preparedness and response:**
- Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential
- Sustaining established coordination mechanisms for European adaptive platform trials and/or for cohort networks
- Understanding vaccine induced-immunity
- Immunogenicity of viral proteins of viruses with epidemic and pandemic potential

**2024 Call (Two Stage)**
(First Stage Deadline 19 Sept 2023 tbc)

- Comparative effectiveness research for healthcare interventions in areas of high public health need
- Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders
- Tackling high-burden for patients under-researched medical conditions
- Adaptive platform trials for pandemic preparedness

**2024 Call (Single Stage)**
(Deadline 11 April 2024 tbc)

- Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness
- Host-pathogen interactions of infectious diseases with epidemic potential

**€401m***
Ensuring access to innovative, sustainable and high-quality health care*

*Excluding Partnerships

**2023 Call (Single Stage)**
(Deadline 13 April 2023 tbc)

- Maintaining access to regular health and care services in case of cross-border emergencies
- Resilience and mental wellbeing of the health and care workforce
- Environmentally sustainable and climate neutral health and care systems

**2024 Call (Two Stage)**
(First Stage Deadline 19 Sept 2023 tbc)

- Access to health and care services for people in vulnerable situations

€90m*

17 projects funded*
Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

<table>
<thead>
<tr>
<th>2023 Call (Single Stage)</th>
<th>2024 Call (Two Stage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Deadline 13 April 2023 tbc)</td>
<td>(First Stage Deadline 19 Sept 2023 tbc)</td>
</tr>
<tr>
<td>Clinical trials of combined Advanced Therapy Medicinal Products (ATMPs)</td>
<td>Innovative non-animal human-based tools and strategies for biomedical research</td>
</tr>
<tr>
<td>Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management</td>
<td></td>
</tr>
<tr>
<td>Better integration and use of health-related real-world and research data, including genomics, for improved clinical outcomes</td>
<td></td>
</tr>
<tr>
<td>Harnessing the potential of real-time data analysis and secure Point-of-Care computing for the benefit of person-centred health and care delivery</td>
<td></td>
</tr>
<tr>
<td>Developing a Data Quality and Utility Label for the European Health Data Space</td>
<td></td>
</tr>
<tr>
<td>Pandemic preparedness and response</td>
<td>Pandemic preparedness and response: In vitro diagnostic devices to tackle cross-border health threats</td>
</tr>
</tbody>
</table>

33 projects funded

€264m

Info based on DRAFT Cluster 1 Work Programme (published 29/11/22)
# Maintaining an innovative, sustainable and globally competitive health industry

## 2023 Call (Single Stage) (Deadline 13 April 2023 tbc)

- Supporting the uptake of innovative Health Technology Assessment (HTA) methodology and advancing HTA expertise across EU
- Expanding the European Electronic Health Record exchange Format to improve interoperability within the European Health Data Space
- Modelling and simulation to address regulatory needs in the development of orphan and paediatric medicines
- Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs)
- Development and harmonisation of methodologies for assessing digital health technologies in Europe

## 2024 Call (Single Stage) (Deadline 11 April 2024 tbc)

- Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)
- Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators

---

**€68m**

13 projects funded
Health Cluster Summary

- **Approx. €1.106 billion** worth funding opportunities*
- At least **44 funding call topics** with calls in 2023 and 2024
- Approximately **162 projects** expect to be funded

- **UK entities are eligible** to apply for Horizon Europe funding
- **UK entities must request European Commission funding** in Horizon Europe proposals

Interested? Next steps

- Read the [draft Cluster 1 (Health) Work Programme (2023-24)](#) which contains full call topic descriptions
- Attend the European Commission Infoday: 19 Jan 2023 (Hold the date) and partnering day 20 Jan 2023 tbc (set up a profile once the online system called ‘B2Match’ is available)
- Be proactive - Start shaping your **project ideas** and seek out **consortium partners**
- You may find the [recording and slides from our ‘Horizon Europe Consortia Building’ event](#) useful.

- **Sign up for our UK newsletter**
- **Contact UK NCP** for more details & support:
  - Tristan Fancourt - contact for academia ([ncp@mrc.ukri.org](mailto:ncp@mrc.ukri.org))
  - Jo Frost - contact for industry ([ncp-health@iuk.ukri.org](mailto:ncp-health@iuk.ukri.org))
  - If you are from another sector (e.g. Charity, Government, NHS) please copy both Jo and Tristan into your email

*Excluding Partnerships
Horizon Europe Health Cluster - Partnerships
Partnerships bring together the European Commission and private and/or public partners together to tackle pressing challenges. General process:

1. Partnership of research funders/policy makers established (sometimes through a call in the Horizon Europe Work Programme)

2. Partnership may hold funding calls (researchers and innovators can apply for funding)
**Horizon Europe - Health: Partnerships**

Partnerships bring together the European Commission and private and/or public partners together to tackle pressing challenges. General process:

1. **Partnership of research funders/policy makers established**
   (sometimes through a call in the Horizon Europe Work Programme)

2. **Partnership may hold funding calls**
   (researchers and innovators can apply for funding)

**European Commission funding 2023/2024 calls to set up new/(follow-on) Partnerships include:**

At this stage, the calls are mainly aimed at funders and policy makers. Researchers and innovators are not normally involved at this stage. Once established, in the future these partnerships can then hold funding calls. Eligibility rules will be specified on a call by call basis.

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
<th>Total Budget</th>
<th>EC Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare Diseases</td>
<td>(to follow-on from EJP RD)</td>
<td>~€100m</td>
<td>€50m</td>
</tr>
<tr>
<td>Personalised Medicine</td>
<td>(to follow-on from ICPerMed)</td>
<td>~€333m</td>
<td>€100m</td>
</tr>
<tr>
<td>One Health AMR</td>
<td>(to follow-on from JPIAMR)</td>
<td>~€333m</td>
<td>€100m</td>
</tr>
</tbody>
</table>
Horizon Europe - Health: Partnerships

Partnerships bring together the European Commission and private and/or public partners together to tackle pressing challenges. General process:

1. Partnership of research funders/policy makers established (sometimes through a call in the Horizon Europe Work Programme)

2. Partnership may hold funding calls (researchers and innovators can apply for funding)

(1) European Commission funding 2023/2024 calls to set up new/(follow-on) Partnerships include:

   - **Rare Diseases** (to follow-on from EJP RD)
     - Total budget ~€100m of which €50m from EC
   - **Personalised Medicine** (to follow-on from ICPerMed)
     - Total budget ~€333m of which €100m from EC
   - **One Health AMR** (to follow-on from JPIAMR)
     - Total budget ~€333m of which €100m from EC

(2) Existing Partnerships which have funding calls you can apply to for R&I projects include:

   - **Innovative Health Initiative (IHI)**
   - **Global Health EDCTP3** (European and Developing Countries Clinical Trials Partnership)
   - **JPIAMR** (Joint Programming Initiative on Anti-Microbial Resistance)
Horizon Europe – Health: Partnerships
Global Health EDCTP3 (European and Developing Countries Clinical Trials Partnership)

Budget €1.6 billion (€800m from European Commission, €400m from EDCTP Association, €400m from other partners such as philanthropic organisations and industry)

This partnership will
• deliver new solutions for reducing the burden of infectious diseases in sub-Saharan Africa, and
• strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and across the world

Goals by 2030
• develop and deploy at least two new technologies tackling infectious diseases, and
• support at least 100 research institutes in 30 countries to develop additional health technologies against infectious diseases

Funding Calls
• 2022 Call opened May 2022 and closed Aug 2022
• 2023 Call timing tbc

✅ UK based organisations are eligible for funding from EDCTP calls (even if the UK does not Associate to Horizon Europe)
This is because the UK is a member of the EDCTP Association.

Further Info
• Global Health EDCTP3 website including their Strategic Research and Innovation Agenda (SRIA)
• Website of previous iteration of EDCTP (EDCTP2)
Horizon Europe
Cancer Mission

Slides happily shared!
Cancer Mission

**Goal:** Improve the lives of more than 3 million people by 2030, through prevention, cure and for those affected by cancer including their families, to live longer and better (jointly with Europe’s Beating Cancer Plan)

### 2023 Call (Single Stage)
*(Deadline 12 April 2023 tbc)*

<table>
<thead>
<tr>
<th><strong>Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Enhance primary cancer prevention through sustainable behavioural change</strong></td>
</tr>
<tr>
<td><strong>Pragmatic clinical trials on minimally invasive Diagnostics</strong></td>
</tr>
<tr>
<td><strong>Establish best practices and tools to improve the quality of life for childhood cancer patients, survivors and their families in European regions</strong></td>
</tr>
</tbody>
</table>

### 2024 Calls

**Call topics are tbc**

**Hold the dates:**

17-18 Jan 2023 Infodays on Missions, including:
17 Jan: 1-3pm (UK time) Cancer Mission Info Session
18 Jan: Cancer Mission Brokerage Event

---

A mission is a portfolio of actions across disciplines intended to achieve a **bold, inspirational and measurable goal** within a set timeframe, with **impact** for society and policy making as well as relevance for a significant part of the European population and wide range of European citizens.
Thank you
Innovative Health Initiative (IHI)

Elisabetta Vaudano
Responsible Strategic Area Neuroscience
The Innovative Health Initiative: an introduction and future opportunities
IHI in a nutshell
IHI is a collaboration between the EU and the biopharmaceutical, biotechnology, digital health and medical technology sectors, as well as academics, patients, regulators and other healthcare professionals.

IHI will build on the extensive experience of IMI’s 14 years and almost 200 projects to build an interdisciplinary, sustainable, patient-centric health research partnership to help transform patients’ lives.

The industry members that make up the new partnership are:
- COCIR
- EFPIA
- EuropaBio
- MedTech Europe
- Vaccines Europe

The public member in the partnership is the European Union, represented by the European Commission.

Innovative Health Initiative
## IHI Trade associations at a glance

<table>
<thead>
<tr>
<th>Trade Association</th>
<th>Represents</th>
<th>Mission/Vision</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>efpia</strong></td>
<td>Pharmaceutical industry</td>
<td>To create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.</td>
</tr>
<tr>
<td><strong>COCIR</strong></td>
<td>Medical imaging, radiotherapy, health ICT and electromedical industries</td>
<td>Our industry provides safe and high quality products and services, which contribute to reducing health inequalities and enhance cost efficiency in healthcare systems. COCIR’s key objective is to promote free worldwide trade of innovative medical technology while maintaining the competitiveness of the European medical imaging, radiotherapy, electromedical and health ICT industries.</td>
</tr>
<tr>
<td><strong>MedTech Europe</strong></td>
<td>Medical Technology industry</td>
<td>Make innovative medical technology available to more people, while helping healthcare systems move towards a more sustainable path.</td>
</tr>
<tr>
<td><strong>Vaccines Europe</strong></td>
<td>Vaccine industry</td>
<td>To support broad access to immunisation, enabling better protection of the health of individuals and the wider community throughout life, with both existing vaccines and those in development.</td>
</tr>
<tr>
<td><strong>EuropaBio</strong></td>
<td>Biotech industry</td>
<td>Committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy.</td>
</tr>
</tbody>
</table>
- A new Strategic Research and Innovation Agenda
- The Science and Innovation Panel
- One and two stage calls

- The way we’re governed will change.
- The scope of the partnership is broader than IMI as it will cover the entire continuum of care.
- There will be new, specific objectives that align with the EU’s latest health policy strategies.
- Funding comes equally from the public and industry partners.
- Calls for proposals will be open and competitive.
- Projects started under IMI will be managed by IHI.
IHI JU Budget

IHI will work to reach its objectives with the following resources:

- up to EUR **1.2 billion** provided by the European Union (Horizon Europe Health Cluster),
- at least EUR **1.0 billion** provided by the member industry associations,
- up to EUR **200 million** from Contributing Partners.
Strategic Research & Innovation Agenda

Focus

- Cross-sectoral approaches to facilitate creation of new products and services to prevent, intercept, diagnose, treat and manage diseases and foster recovery more efficiently.

Goal

- Lay foundations for development of safer and more effective health care products or solutions that respond to unmet public health needs and that can be implemented into healthcare systems.

Research supported by IHI should remain at precompetitive level
IHI Specific objectives

a. Improve our understanding of the factors that affect our health and the development and treatment of certain diseases.

b. Integrate fragmented health research and innovation efforts by bringing together health industry sectors and other stakeholders. This will enable the development of tools, data, platforms, technologies and processes to facilitate the prevention, diagnosis, treatment and management of diseases, especially in areas of unmet public health need.

c. Demonstrate the feasibility of integrated healthcare solutions that draw on various technologies from different sectors and address the needs of the people who will use them, such as patients and healthcare professionals.

d. Make better of opportunities to gather health data and use it in research and care, all while respecting relevant privacy legislation.

e. Develop ways of assessing the value of innovative, integrated health care solutions to patients, carers, healthcare professionals and organisations, and other stakeholders.
Apply to IHI calls
2 types of calls for proposals

**single-stage**

- Broad topic, not specific to one single product/technology/solution
- Private Members apply simultaneously with Public Members in mixed consortia
- Due to its nature of openness and competitive character, private members can receive funding
- Pharma companies will abstain from requesting funding
- Industry is building consortia alongside with public partners (like in HE regular calls)
- Budget includes at least 45% in-kind contribution (e.g., 10 million total budget: up to 5.5 mln costs funded by IHI, at least 4.5 in-kind provided by members of founding associations)

**2-stage**

- Targeted topics and budget are determined by Private Members
- Anyone interested can subscribe to these calls, in line with available funding
- Winning consortium is coupled to Private Members’ consortium to prepare second stage full proposal
- Due to its nature of company-detailed topics, Private Members are not eligible for funding
- In fact, no funding will be made available for any company with annual turnover > 500M
- The industry consortium is built first, and then the public consortium is built separately
Next IHI calls

IHI call 3 (single stage call) - updated drafts of 24 November 2022

- Topic 1: Screening platform and biomarkers for prediction and prevention of diseases of unmet public health need
- Topic 2: Patient-generated evidence to improve outcomes, support decision making, and accelerate innovation
- Topic 3: Combining hospital interventional approaches to improve patient outcomes and increase hospital efficiency
- Topic 4: Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases
- Topic 5: Digital health technologies for the prevention and personalised management of mental disorders and their long-term health consequences

IHI call 4 (two stage call) - updated drafts of 24 November 2022

- Topic 1: Expanding translational knowledge in minipigs: a path to reduce and replace non-human primates in non-clinical safety assessment
- Topic 2: Patient-centric blood sample collection to enable decentralised clinical trials and improve access to healthcare

Read more about the topic ideas
Entities eligible to participate
Attracting stakeholders

Any legal entity, regardless its place of establishment, carrying out work relevant to the Call objectives may be part of applicant consortia.

But… not all participating entities are eligible for funding.
Eligibility

Consortium composition (collaborative projects)

- at least **one independent legal entity** established in a **Member State**, and
- at least **two other independent legal entities** each established either in a **different Member State** or an **Associated Country**.

**EU COUNTRIES**

- Member States (MS) including their outermost regions
- The Overseas Countries and Territories (OCTs) linked to the MS.

**NON-EU COUNTRIES**

- Countries associated to Horizon Europe (AC)
- Low and middle income countries: See **HE Programme Guide**.

**COUNTRIES ASSOCIATED TO HORIZON EUROPE**

- Association agreements produce legal effects
- Transitional arrangements

- UK is treated as an associated country throughout the process - and as such can/should request JU funding. Grant agreements can only be signed if the association has come into force.

- Switzerland is currently not covered by the transitional arrangement.
EU restrictive measures

Special rules apply for entities from certain countries

• Given the invasion of Ukraine by Russia and the involvement of Belarus:
• Legal entities established in Russia, Belarus, or in non-government controlled territories of Ukraine are not eligible to participate in any capacity.
Entities eligible for funding
Eligibility rules: funding

Any legal entity established in a Member State, Associated Country or Low and Middle Income Countries

Third country to Horizon Europe legal entities are normally not eligible for receiving IHI funding

See Horizon Europe programme guide

exceptional funding (recommended by experts evaluators) when it considers that their participation is essential

Eligibility rules: funding
Eligibility for funding in single-stage Calls

- Non-profit organisations
- Academics
- Hospitals
- NGOs
- research organisations
- Patients' Organisations
- intergovernmental organisations

- For-profit legal entities (both SME and larger enterprises)
Eligibility for funding in **two-stage** Calls

Non-profit organisations

For-profit legal entities
(SME and larger enterprises with an annual turnover of **less than EUR 500 million**)

**NOT** eligible for funding:
- Pre-identified Industry Consortium
- For-profit company:
  
  (a) with an annual turnover of **EUR 500 million or more**
  (b) directly or indirectly controlling/or being controlled by for profit legal entities with an annual turnover of **EUR 500 million or more**.
IHI JU Specific types of Beneficiaries

**Private member**
Any legal entity established under public or private law (including constituents and/or affiliates) that is member of one of the Industry Associations.

**Constituent entities** means the entities that constitute a private member of a joint undertaking, where the private member is an association according to that member’s statutes.

**Affiliated entity** means the entity that has a capital or legal link with a beneficiary (which is in this case a private member or a private member constituent entity)

**Contributing Partner** legal entities interested in supporting IHI JU’s objectives in their specific areas of research, without becoming a member; it participates in the Consortium and provides in kind or financial contributions but is not providing in-kind contributions to additional activities (IKAA)
Contribution types

- **IKOP** - In-kind contributions to OPerational activities
  Eligible costs incurred in implementing an IHI project
  Can be Non-EU IKOP or EU IKOP

- **FC** - Financial contributions
  Cash contributions to project beneficiary(ies) from the same consortium to support eligible costs for project implementation

- **IKAA** - In-kind contributions to Additional Activities
  Costs for implementing additional activities *(NEW, no IKAA in IMI2)*

*Private members, their constituents or affiliated entities* can contribute IKOP, IKAA and FC. *Contributing partners* can contribute IKOP and FC, not IKAA.

https://www.ihi.europa.eu/shape-our-future-research/become-contributing-partner
Tips and tricks

For preparing a successful proposal:

- Start working as early as possible and do not submit at the last moment.
- Network, network, network!
- Read carefully all Call documentation on the IHI website as well as in the HE Portal and participate to webinars and brokerage events.
- "Think public-private partnership" at all level of your proposal and consortium.
- Remember that the 45%* contributions to total costs is an eligibility criterion.
- Reach out to IHI office for any question you may have

* If during project implementation the contributions drop below 45% the action will lose eligibility status, thus a prudent approach aiming at having around 50% contributions is recommended
IHI calls – find out more & find partners

You’ll need to build or join a consortium!

- Read the draft call texts as soon as they’re published and start networking early
- Follow our information days
- Participate in our online Brokerage events
- Use online partner search tools (e.g. on the Funding & Tenders portal)

More tips:

www.ihi.europa.eu/apply-funding/find-partners
www.ihi.europa.eu/apply-funding/future-opportunities
Shape our future research
Send us your ideas for IHI projects

- Many ideas for call topics come from our partners (industry members and the European Commission) and from contributing partners, but we also welcome ideas from the wider health and research community.

- All ideas will have to demonstrate
  - how they would help IHI to achieve its goals;
  - how they are aligned with the IHI SRIA;
  - why they need a cross-sectoral public-private partnership.

- Ideas will be assessed by the IHI Programme Office and governance bodies.

- We have developed a web-supported platform to make it easy for people to submit call topic ideas.

https://www.ihi.europa.eu/shape-our-future-research/proposal-ideas
Stay in touch

- Website: www.ihi.europa.eu
- Sign up for our monthly newsletter: www.ihi.europa.eu/news-events/newsletter
- Follow us on
  - Twitter: @IHI_Europe
  - LinkedIn: Innovative Health Initiative (IHI)

Questions?

- E-mail us: infodesk@ihi.europa.eu
Thank you for your attention
Joint Programming Initiative on Antimicrobial Resistance

Laura Marin
JPI AMR Head of Secretariat
Joint Programming Initiative on Antimicrobial Resistance

JPIAMR

Laura Marin,
JPIAMR Head of Secretariat

02 December 2022
JPIAMR: a global platform supporting AMR research

Uniting 29 countries to address AMR

The European Commission (DG Research) is a full non-voting member

- Aligns, prioritises and coordinates AMR research funding
- Supports One Health AMR research on a global scale
- Disseminates and exploits AMR research results
- Interface with global policy activities

www.jpiamr.eu    twitter.com/JPIAMR    facebook.com/JPIAMR
JPIAMR supporting the AMR research community

**Total Investment**
- 143 M€

**Researcher Location**
- 34 LMICs involved
- 117 researchers from LMICs
- 43 research project and networks with LMIC elements in their research scope

**Projects**
- 156
- 112

**Networks**
- 44

**Researchers**
- 1730
- From 77 different countries

**One Health perspective**
- 42% Projects with One Health aspect
JPIAMR: A global One Health AMR Research Funder

**Environment**
- Transmission routes in environment
- Surveillance of non-human AMR reservoirs (wildlife, wastewater)

**Surveillance**
- Improvement of Surveillance tools and technologies
- Standardisation of methods

**Diagnostics**
- New rapid diagnostics and point-of-care techniques
- AMR detection in multiple reservoirs

**Therapeutics**
- Discovery of new antimicrobials and therapeutic alternatives
- New target identification
- Repurposing of drugs

**Transmission**
- Transmission mechanisms and routes
- Strategies to inhibit or reduce AMR transmission
- Risk assessment

**Interventions**
- Interventions for infection prevention and control measures
The OH AMR Partnership 2025-2032; a joint research programme
Identifying OH research priorities 2025-2032

• Introduction conference (Towards a OH AMR partnership, February)
• Initial global consultation (survey, April)
• Antibacterial resistance (Early Career Scientist workshop, June).
• Antifungal resistance (webinar, June).
• Antiparasitic resistance (survey and webinar September)
• Antiviral resistance (survey and webinar September)
• Surveillance (workshop March)
• Transmission & Evolution (thematic group meeting on June)
• Prevention and Intervention (roundtables: June)
• Vaccines (Webinar, June)
• Innovation (2 workshops: one on therapeutics and one on diagnostic and surveillance, June).
• Environmental dimensions (round table during the EDAR6 meeting, September)
• Social Sciences expert group consultations
• Stakeholders consultations and end-users community groups consultations (November)
• Member states consultations (March/October/December)
  • Monthly alignment meetings with WHO/Quadripartite; Final Member states consultations (March); Prioritisation workshop (May) 2023)
Pre-announcement: AMR Diagnostics and Surveillance Call 2023

- Participating countries: Australia, Belgium, Canada, Estonia, France, Germany, Ireland, Israel, Italy, Lithuania, Moldova, Netherlands, Poland, South Africa, Spain, Sweden, Switzerland & the UK

For the UK:
- Those eligible for UKRI funding from Innovate UK, MRC, BBSRC or EPSRC* can be funded by the JPIAMR call
- Innovate UK funding is for any eligible ‘One Health’ area
- The funding for UK organisations for the JPIAMR call comes from UKRI, so is not dependant on UK Association to Horizon Europe

- Estimated budget: €18.8 Million
- Preannouncement
  Topic 1: To develop novel or improve existing diagnostics
  Topic 2: To develop or improve existing strategies, technologies or methods to support OH AMR surveillance
- Call opens on 10 January 2023
- Info webinar 24 Jan
- www.jpiamr.eu and @jpiamr

* Medical Research Council (MRC), Biology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council (EPSRC)
For more information:

Subscribe to the JPIAMR newsletter

Follow JPIAMR on social media

Follow any updates from national agencies
Health Opportunities under the European Research Council (EIC)

Claire Griffin
NCP for EIC
Horizon Europe
European Innovation Council (EIC)

Claire Griffin
UK NCP for EIC
Horizon Europe Structure

Pillar 1: EXCELLENT SCIENCE
- European Research Council
- Marie Skłodowska-Curie Actions
- Research Infrastructures

Pillar 2: GLOBAL CHALLENGES, EUROPEAN INDUSTRY COMPETITIVENESS
- Clusters:
  - Health
  - Culture, Creativity and Inclusive Society
  - Civil Security for Society
  - Digital, Industry and Space
  - Climate, Energy and Mobility
  - Food, Bioeconomy, Natural Resources, Agriculture and Environment
- Joint Research Centre

Pillar 3: INNOVATIVE EUROPE
- European Innovation Council
- European innovation ecosystems
- European Institute of Innovation and Technology

WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA
- Widening participation and spreading excellence
- Reforming and Enhancing the European R&I system

Find a UK NCP
EIC Main Characteristics

▪ Identify, develop and deploy high risk innovations of all kinds
▪ From Idea to Market
▪ Focus on breakthrough, market-creating, deep-tech
▪ Steered by EIC Board of leading innovators
▪ Business Acceleration Services
▪ Pro-active management with EIC Programme Managers
▪ Follow-up funding for results from Horizon (e.g. ERC, EIT)
Main funding instruments

- **EIC Accelerator**
  - Development & Scale-up
  - €2.5M

- **EIC Transition**
  - Technology Maturation
  - €2.5M

- **EIC Pathfinder**
  - Early Stage Research
  - €3M / €4M

# Draft Call Deadlines & Budget for 2023

<table>
<thead>
<tr>
<th>Open Calls</th>
<th>Budget (EUR M)</th>
<th>Challenge Calls</th>
<th>Budget (EUR M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIC Pathfinder</td>
<td>7 March 2023</td>
<td>179.50</td>
<td>18 October 2023</td>
</tr>
<tr>
<td>EIC Transition</td>
<td>12 April 2023</td>
<td>67.86</td>
<td>4 May 2022</td>
</tr>
<tr>
<td></td>
<td>27 September 2023</td>
<td></td>
<td>28 September 2022</td>
</tr>
<tr>
<td>EIC Accelerator</td>
<td><strong>Short applications:</strong> Continuous Full applications: 11 January 2023 22 March 2023 7 June 2023 4 October 2023</td>
<td><strong>Short applications:</strong> Continuous Full applications: 22 March 2023 7 June 2023 4 October 2023</td>
<td><strong>Short applications:</strong> Continuous Full applications: 22 March 2023 7 June 2023 4 October 2023</td>
</tr>
</tbody>
</table>
EIC - Open or Challenges

Open
- Bottom-up.
- Any field of science, technology or application without predefined thematic priorities

Challenges
- Top-down, challenge driven, portfolios of project approach.
- To support proposals within a predefined thematic area and addressing specific objectives
EIC Pathfinder

Who can apply

▪ At least 3 different independent legal entities in at least three different eligible countries

What for?

▪ Grants of up to 4M€

▪ To achieve the proof of principle and validate the scientific basis of breakthrough (TRL 1-4)
EIC Pathfinder Challenges 2023

- Clean and efficient cooling
- Architecture, Engineering and Construction (AEC) digitalisation
- Precision nutrition
- Responsible electronics
- In-space solar energy
EIC Pathfinder – Precision Nutrition

- Diet is contributor to human health
- Dietary guidelines do not stratify dietary recommendations across gender, age, ethnicity, genetic predisposition etc
- Fund multi-disciplinary research proposal that include nutritional, microbiome and glycan research aspects
  - Beyond state-of-the art
  - Better clarify the role of diet into human health
  - Including whole plant foods, high processed meat and fermented food with human gut microbiome and glycans.
- Build on work carried out by European Food and Safety Authority (EFSA)
Specific objectives

- Confirm and quantify causal relationships among diet, microbiome and glycans, with strong emphasis on factors with significant stratifying effect on human diet. Provide scientific evidence to stratify dietary

- Identify food ingredients, food technology processes, additives and dietary patterns that have detrimental effects on human health, aging, the microbiome and the glycome

- Identify food ingredients, food technology processes and additives that have beneficial effect on human health, aging, the microbiome, the glycome and later expression of NCDs

- Provide scientific evidence to stratify dietary recommendations for targeted microbiome modulation.

- Provide scientific evidence and process/product development recommendations for the reformulation of processed food with no- or less additives.

- Provide scientific evidence and process/product development recommendations for the design of novel foods tailored to stratified/ individual dietary needs.
Expected outcomes and impacts

- By laying the foundation for microbiome restoration strategies and understanding the links between diet and human health and pathology:
  - prevent and alleviate the consequences of obesity and NCDs on health and wellbeing
    - by paving the way towards the production of novel foods, tailored to stratified/individual dietary requirements and
    - building on an evidence-based upgrade of the current dietary guidelines.
  - Decreased incidence of NCDs and obesity among the general population, and a better quality of life for the individuals affected by these conditions.
EIC Transition

Who can apply?

▪ Build on Eligible funded projects (EIC Pathfinder, FET (open, proactive & Flagship, ERC PoC, EDF (Civil applications))

▪ **Single applicants** (SMEs, spin-offs, start-ups, research organisations, universities) or **small consortia** (two partners) or **consortia of three to five different** independent legal entities established in at least three different eligible countries.

What for?

▪ Grants of up to 2.5M€ to validate and demonstrate technology in application relevant environment (TRL4 to 5/6)
EIC Transition Challenges

- Micro-Nano-Bio devices for medical and medical research applications
- Environmental intelligence
- Chip-scale optical frequency combs
Full Scale Micro-Nano-Bio devices for medical and medical research applications

- to realise and validate a fully functional integrated Micro-Nano-Bio device or system
- Focus is on integration and/or refinement of a transitionable investment-ready product.
- Lead to a high-impact technological development driven by market needs.
- Can rely on high-performance computing and advanced Artificial Intelligence (AI) / Machine Learning (ML)
Expected outcomes and impacts

▪ Realisation of significant progress in Micro-Nano-Bio systems to a level of technological maturity suitable for exploitation.

▪ Positioning the European Micro-Nano-Bio ecosystems at the leading edge of product innovation, supporting global market leadership.

▪ An exploitation strategy and a credible business model
  ▪ its initial validation and a business plan are also expected outcomes of the project with the goal of attracting private investors and industrial partners.
EIC Accelerator

Who can apply?

▪ Single start-ups and SMEs (including spin-outs),
▪ individuals (intending to launch a start-up/ SME) and
▪ in exceptional cases small mid-caps (fewer than 499 employees)

What for?

▪ Grant only (UK Based) – 70%
▪ Up to €2.5M for innovation activities (up to TRL8)
EIC Accelerator Challenges

Emerging and strategic technologies

- Biomarker assays for cancer
- Decontamination for pandemic management
- Energy storage
- New European Bauhaus
- Quantum computers and quantum sensors
- Semiconductors
- Novel tech for Resilient Agriculture
- Space technologies and services
Novel Biomarker-based assays to guide personalised cancer treatment

- Aims to improve efficacy, safety and uptake of therapeutic approaches against refractory cancers, using novel comprehensive predictive, prognostic and companion diagnostic tests, in the context of precision oncology.
- Design novel and effective ways to predict, guide and monitor the progression of a disease in patients afflicted by refractory cancers
- Develop comprehensive multimodality predictive tests
- Make more accurate prognosis on which patients, among those who underwent treatment, are more likely to recur
Outcomes

- Identify, who is more likely to benefit from guided treatment,
- Identify, who with potentially precancerous lesions, is more likely to develop cancer,
- Identify, who among the cancer patients having undergone treatment, is more likely to recur,
- Identify who among the cancer patients receiving treatment, is more likely to develop side effects as a result of the treatment, affecting their quality of life, and
- More effectively monitor the clinical course of the disease
- Europe establish the basis for a globally competitive biotech portfolio
Aerosol and surface decontamination for pandemic management

Objectives:

- Full systems for high-efficiency aerosol capture, pathogen deactivation and air circulation management in closed-environments including advanced air-filtering architectures and dynamic air circulation optimisation.

- Next-generation face mask technologies with smart filtration materials to exceed N95 performance at low airflow resistance, with improved retention/rejection of sub-micron particles.

- Rapid surface decontamination devices beyond state-of-the-art UV-C irradiation systems and biocidal agent dispersion.
Outcomes and impacts

- By reducing the need for social distancing in the event of infectious pandemics, this Challenge will empower society at large to sustain unaltered economic and social dynamics in the event of pandemic outbreaks.
Challenges workshop for 2024 onwards

- 22 – 27th September 2022
- Discussion on applied methodology + outcome expectations
- Medical Technologies and Medical Devices
- Health & Biotech
- Available – individual reports
  - EIC Challenges Workshop with Member States (europa.eu)
Thank you

Claire.griffin@iuk.ukri.org

@uk_eic_ncp or +44 7517 830 086

Twitter:@InnovateUK   Facebook: Innovate UK   YouTube: Innovate UK
Health Opportunities under the European Research Council (EIC)

Alice Chadwick
NCP Research Infrastructures
Horizon Europe: Research Infrastructures

Research Infrastructures: facilities providing resources and services for the research communities to conduct research and foster innovation (single site, distributed, virtual).

Providing access to external users, could be:
• knowledge related (archives, data infrastructures)
• major scientific equipment (telescopes, research vessels)
• ICT infrastructures (computing systems, communication networks)

Research Infrastructures contribute to:
1. Extend the frontiers of knowledge
2. Exchange and transmit knowledge
3. Train the next generation of top researchers
4. Support industrial innovation

Within Pillar 1: Excellent Science, alongside ERC and MSCA, with €2.4bn funding
The purpose of the RI Programme

Is not:
• building RIs. MS and third countries come together to build RIs with Structural Funds and National Funding/in-kind contributions. Funding capital costs (with some exceptions)

It is aiming to:
• Develop an advanced RI system for the European Research Area (ERA)
• Support Trans-National & Virtual Access to RI
• Facilitate MS agreement on roadmaps for future pan-European RIs and RI upgrades via ESFRI
• Foster international cooperation of facilities, links with the private sector, and compliance with the European Open Science Cloud
# RI and Health

<table>
<thead>
<tr>
<th>Topic reference number</th>
<th>Topic title</th>
<th>Funding action</th>
<th>Indicative size (€ million)</th>
<th>Indicative budget (€ million)</th>
<th>No. projects</th>
</tr>
</thead>
<tbody>
<tr>
<td>HORIZON-INFRA-2023-DEV-01-01</td>
<td>Concept development for a research infrastructure to manage, integrate and sustain large medical cohort studies</td>
<td>RIA</td>
<td>3</td>
<td>1-3</td>
<td>1</td>
</tr>
<tr>
<td>HORIZON-INFRA-2023-SERV-01-01</td>
<td>Research infrastructure services to enable R&amp;I addressing main challenges and EU priorities: • For RI services to enable research linking environmental factors to human health • For RI services for improving clinical research in the paediatric area</td>
<td>RIA</td>
<td>116</td>
<td>8-14.5</td>
<td>8</td>
</tr>
</tbody>
</table>

Information based on the DRAFT work programme; may be subject to change

NCP for RI: Alice Chadwick, RINCPUK@stfc.ac.uk
Horizon Europe – Other opportunities for Health Research

Jo Frost
NCP for Health (Cluster 1)
Horizon Europe – Other Opportunities

- Research Infrastructures
- European Research Council (ERC)
- Marie Skłodowska-Curie Actions (MSCA)
- Eurostars
- COST
- European Institute of Innovation and Technology (EIT) Health
- Euratom

2 December 2022
Jo Frost - UK Health National Contact Point (NCP) for Health (ncp-health@iuk.ukri.org)
Alice Chadwick – UK NCP for Research Infrastructures (alice.chadwick@stfc.ukri.org)
Why look for funding outside the Health Cluster too?

- **In Horizon Europe** there are different opportunities across the programme, for example:
  - Some calls have ‘top-down’ prescribed R&I areas - you need to do exactly what the Commission wants! (e.g. Pillar 2 incl. Health Cluster)
  - Some calls are open to all R&I areas (e.g. the ERC, MSCAs, some EIC projects and COST)
  - Some calls do not require a consortium (e.g. ERC, MSCA fellowships)
  - Some calls fund networking (e.g. MSCA Staff Exchange Scheme and COST)
- **In Horizon 2020** (the EU’s Research and Innovation Programme 2014-2020):
  - 29% of projects including Health and Medical Sciences were funded in the Health Challenge
  - 71% of projects including Health and Medical Sciences were funded outside of the Health Challenge

---

**H2020 Funding for projects including Health & Medical Sciences**

- ~29% ERC
- ~16% MSCA ~4% FET
- ~2% Infrastructures

*Data Source: EU Horizon Dashboard, 16 Mar 21*
Horizon Europe – Research Infrastructures

Pillar I
EXCELLENT SCIENCE
European Research Council
Marie Skłodowska-Curie
Research Infrastructures

Pillar II
GLOBAL CHALLENGES & EUROPEAN INDUSTRIAL COMPETITIVENESS
- Health
- Culture, Creativity & Inclusive Society
- Civil Security for Society
- Digital, Industry & Space
- Climate, Energy & Mobility
- Food, Bioeconomy, Natural Resources, Agriculture & Environment
Joint Research Centre**

Pillar III
INNOVATIVE EUROPE
European Innovation Council
European innovation ecosystems
European Institute of Innovation & Technology*

WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA
Widening participation & spreading excellence
Reforming & Enhancing the European R&I system
Horizon Europe – Pillar I – Research Infrastructures - €2.4 billion 2021-2027

Is not:
X building Research Infrastructures (RIs)
X funding capital costs (with some exceptions)

It is aiming to:
✔ Develop an advanced RI system for the European Research Area (ERA)
✔ Support Trans-National & Virtual Access to RI
✔ Facilitate EU Member State agreement on roadmaps for future pan-European RIs and RI upgrades via ESFRI (European Strategy Forum on Research Infrastructures)
✔ Foster international cooperation of facilities, links with the private sector, and compliance with EOSC (European Open Science Cloud)

Some example call topics (from draft 2023-2024 Work Programme, published 29/11/22)
- Concept development for a research infrastructure to manage, integrate and sustain large medical cohort studies
- Research infrastructure services to enable R&I addressing main challenges and EU priorities [priorities include: linking environmental factors to human health; improving clinical research in the paediatric area: innovative applications of nanoscience and nanotechnology (including reducing health risks)]
- New digital twins for Destination Earth (mentions Health)
- AR/VR-empowered digital twins for modelling complex phenomena in new RI application areas (mentions Healthcare as a potential application area)
- Strengthen the bilateral cooperation on research infrastructures with Latin America (Health is one of the priority areas)
Further example call topics (from draft 2023-2024 Work Programme, published 29/11/22)

- Preparation of common strategies for future development of Research Infrastructure (RI): technologies and services within broad RI communities

- Research infrastructure concept development

- Strengthen the bilateral cooperation on research infrastructures with Africa

- Various topics related to:
  - EOSC (European Open Science Cloud) some of which mention the European Health Data Space
  - 'FAIR' data
  - Science software and code
Horizon Europe
Main ‘bottom-up’ opportunities

Pillar I
EXCELLENT SCIENCE
- European Research Council
- Marie Skłodowska-Curie
- Research Infrastructures

Pillar II
GLOBAL CHALLENGES & EUROPEAN INDUSTRIAL COMPETITIVENESS
- Health
- Culture, Creativity & Inclusive Society
- Civil Security for Society
- Digital, Industry & Space
- Climate, Energy & Mobility
- Food, Bioeconomy, Natural Resources, Agriculture & Environment
- Joint Research Centre**

Pillar III
INNOVATIVE EUROPE
- European Innovation Council
- European innovation ecosystems
- European Institute of Innovation & Technology*

WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA
- Widening participation & spreading excellence
- Reforming & Enhancing the European R&I system

Includes successor to Eurostars – in UK funds SMEs but not academia

Includes COST
Long term funding of ground-breaking curiosity lead, investigator-driven ‘frontier research’

Funds a Principal Investigator (PI) and their team.

Across ALL research fields - completely bottom-up

Projects are selected for funding purely based on the excellence (of the PI and of the research project)

Main types of funding:
- Starting Grants
- Consolidator Grants
- Advanced Grants
- Synergy Grants

Like more info? UK National Contact Point: erc-uk@ukro.ac.uk / website / events.
ERC Website including page on grant schemes / newsletter (sign up at the bottom of the ERC Website)
MSCA Staff Exchange Scheme
• Funds short-term exchanges of personnel between academic, industrial and commercial organisations throughout the world

MSCA Doctoral Networks
• Provides full funding for an international consortium to train a group of PhD students. Provides recruited researchers with training through research
• Mobility is key – intersectoral, interdisciplinary and international!

MSCA Post Doctoral Fellowships
• Provides full funding for an individual postdoctoral researcher
• Mobility is key – intersectoral, interdisciplinary and international!

MSCA COFUND Doctoral and Fellowship Programme

NEW: Extra 6 months funding for fellow to spend time in non-academic setting

Like more info? UK National Contact Point: mariecurie-uk@ukro.ac.uk / website / training events
Eurostars

- Eurostars is a joint programme between Eureka and the European Commission
  - It is co-funded from the national budgets of participating Eureka member countries
- Funds transnational, market-oriented, collaborative R&I projects
  - Projects must be initiated and driven by Research and Development performing SMEs
  - Normally bi-annual calls which are open in scope (next call opens July and closes Oct 2021 tbc)
- There are over 45 Eureka member countries including the UK
  - 36 of these countries take part in the Eurostars programme including non-European countries such as Canada, South Korea and South Africa
- Projects can be both bilateral and multilateral
  - For example a UK SME collaborating with an SME/other organisations from any other participating Eureka member country (does not have to be an SME from an EU Member State)
  - The rules about which countries and which types of organisations are funded are explained in the call documents.
- Taking part in a Eurostars project can help growth, innovation, open new global markets and lead to greater business success
- ~1/3 of projects centre around Health and Life Sciences, 1/3 of projects centre around the Data and ICT economy, and a 1/3 are mix of several other sectors

Other Eureka funding schemes

- Globalstars – Funds projects involving Eureka and non-Eureka countries - each call specifies the countries involved
- Network Projects
- Eureka Clusters

Like more info? UK contact Ben Morris / Eurostars contacts in each country
Eureka and Eurostars websites / Subscribe to the Eureka/Eurostars newsletter
Horizon Europe - Widening participation and strengthening the European Research Area (ERA)

Includes COST (European Co-operation in Science and Technology):

- **COST Open Call** (regular deadlines, next deadline 25 Oct 2023 12pm CET)
  - Open to all areas of research and innovation (bottom-up)
  - Funding to set up interdisciplinary research and innovation networks in Europe and beyond
    - Funding for organising meetings, training schools, short term scientific missions or other networking
    - Networks run for 4 years and help to build capacity.
  - Funds global networking of nationally-funded research.
  - In Horizon 2020, COST had a high success rate of 37%
  - You can also join the many existing COST actions
    - e.g. European Network for Optimisation of Veterinary Antimicrobial Treatment – website / newsletter

✅ UK (and Swiss) organisations are eligible for funding (irrespective of whether the UK/Switzerland associate to Horizon Europe)

More info? COST website / COST newsletter / Eligible countries / Contact Points
COST– Information Event on 23 Feb 2021 – recording available
Horizon Europe – EIT

Pillar I
EXCELLENT SCIENCE
- European Research Council
- Marie Skłodowska-Curie
- Research Infrastructures

Pillar II
GLOBAL CHALLENGES & EUROPEAN INDUSTRIAL COMPETITIVENESS
- Health
- Culture, Creativity & Inclusive Society
- Civil Security for Society
- Digital, Industry & Space
- Climate, Energy & Mobility
- Food, Bioeconomy, Natural Resources, Agriculture & Environment
- Joint Research Centre**

Pillar III
INNOVATIVE EUROPE
- European Innovation Council
- European innovation ecosystems
- European Institute of Innovation & Technology*

WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA
- Widening participation & spreading excellence
- Reforming & Enhancing the European R&I system
Horizon Europe – Pillar III – European Institute of Innovation and Technology Knowledge and Innovation Communities (EIC KICS)

- The EIT brings together business, education and research bodies to create an environment conducive to innovation and entrepreneurship in Europe
- It funds 8 long-term partnerships, KICs, each with a focus on a different societal challenges:
  - New KICs for Culture and Creative Industries and Water, Marine and Maritime Sectors and Ecosystems are anticipated in 2022/3 and 2026 respectively

- You can apply to calls for proposals (if eligible) and you can apply to become a partner at any time
- Calls for proposals are primarily open for existing partners. However, non-partners are able to participate

Like more info? UK NCP Ben.Morris@iuk.ukri.org
EIT Managing Director for UK/Ireland graham.armitage@eithealth.eu
Useful links: EIT Website / Link to all EIT KICS / All EIT Opportunities EIT Health
EIT Health

- EIT Health brings together the worlds of business, research, education and healthcare delivery to answer some of the biggest health challenges facing Europe
- One of its aims is to build and grow businesses to develop healthcare products and services
- The EIT Health community includes about 280 organisations
- Between 2016-2021 it has
  - Supported over 1,680 start-ups
  - Trained over 35,880 students and professionals
  - Launched over 70 products and services

- The EIT Health ‘Flagship Call’ has four flagship programmes:
  - New models to deliver healthcare
  - Supporting deployment of Important Project of Common European Interest in Health (IPCEI) to address market failures
  - Facilitating the uptake of digital medical devices in Europe
  - Harnessing the full potential of health data for innovation

- The next cut-offs for submitting short proposals are: 1 March 2023 and 1 June 2023.

- EIT Health held an information session for their Ireland and UK hub, the recording of which is available.
- Questions?
  UK/Ireland: Contact Graham Armitage, Managing Director for UK/Ireland at EIT Health (graham.armitage@eithealth.eu)
  Any Country: Can contact flagships@eithealth.eu

Like more info? UK NCP Ben.Morris@iuk.ukri.org
EIT Managing Director for UK/Ireland graham.armitage@eithealth.eu
Useful links: EIT Website / Link to all EIT KICs / All EIT Opportunities / EIT Health
Euratom
Euratom Research and Training Programme (2021-2025) is a complementary funding programme to Horizon Europe which covers nuclear research and innovation. It uses the same instruments (project types) and rules for participation as Horizon Europe.

Objective
Research and training to reduce nuclear safety and security risks, development of safe nuclear technologies and optimal radiation protection.

Health aspects include
- Increased focus on non-power applications of radiation (e.g. medical, industrial, space)
- “Radiation protection research has led to improvements in medical technologies (e.g. diagnosis and radiotherapy) from which many citizens benefit. This research is leading to further improvements in nuclear medicine as well as in other sectors such as industry.”
- The Euratom programme will expand research into non-power applications of ionising radiation e.g. links with the Horizon Europe Health activities and Europe’s beating cancer plan.
- Opening mobility opportunities for nuclear researchers through inclusion in Marie Skłodowska-Curie Actions.

UK eligibility
The European Commission Q&A on the UK’s Participation in Horizon Europe confirms that “The UK will also be associated to the Euratom Research and Training Programme, as well as fusion-related activities…”
Thank you

Slides happily shared!
Q&A Panel

Viola Hay
Knowledge Transfer Manager
BREAK

Option of watching UKRI video on experiences from Horizon 2020 and Horizon Europe UK grantees

https://www.youtube.com/watch?v=gdxHQ_7VRFg&list=PLkJB0VeI5P_zFLV2oKyywXzZ4Vz2i8Zu
Sharon Brownlow
Chief Business Officer

Cell and Gene Therapy Catapult
SMARTER
Smart MAnufactuRing for Autologous Cell ThERapies enabled by innovative biomonitoring technologies and advanced process control

Sharon Brownlow, CBO
2nd December 2022
Collaboration overview
Project workflow

WP1: CNeT procurement and preparation

WP2: Metabolomics and biomarker discovery

WP3: RAMAN Spectroscopy and chemometric model development

WP4: 2D-fluorescence sensor development, characterisation and performance assessment

WP5: SMART manufacturing demonstration
Enabling international collaboration through complimentary expertise

- Cell therapy Manufacturing
- Data modelling
- cNeT technology
- Bioprocess control
- Spectroscopy Sensors & chemometric data analysis
- Cancer & immune cell metabolomics

Institutes and organizations involved:
- ACHILLES
- CATAPULT
- European Commission
- Leibniz Universität Hannover
- Instituto de Investigación Sanitaria La Fe
Tips on writing a winning application

• SMARTER was classed as an excellent application and scored an overall of 4.93 out of 5. Some feedback:
  • “SMARTER project objectives are highly relevant to the overall goals and specific objectives of the Challenge call by addressing key bottlenecks in TIL and T-cell manufacturing for cancer therapy at several levels.”
  • “This is a highly ambitious proposal aiming to develop a smart bioprocessing manufacturing platform for personalized autologous cell therapies. The project’s objectives are very relevant in contributing to many of the specific objectives of the challenge, including improving adoptive cell therapies and advancing cell therapy manufacturing and products to a clinical stage”
  • “The idea of creating an autologous manufacturing platform with advanced process control to produce the next generation personalized TIL therapy, is a real excellent novel technological breakthrough. The project well describes the current state of the art and provides excellent proofs to go beyond it, in several aspects”

• So:
  • Clearly define an ambitious challenge (relevant to the grant call)
  • Tell the story of how you will solve it and demonstrates impact
  • Make it interesting to read and clear to understand – it will be read by people!
  • Bring together diverse partners with strong complimentary technical background and clearly define their roles in the project
  • Ensure all parties receive the appropriate outputs
  • Set realistic deadlines and prepare the application well in advance!
Funding paving the way to the impact of the SMARTER project

<table>
<thead>
<tr>
<th>Funding source</th>
<th>Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>iUK core Catapult grant funding agreement</td>
<td>Internal capability building</td>
</tr>
<tr>
<td>iUK funding</td>
<td>2 x international CDMO</td>
</tr>
<tr>
<td>Researcher in Residence (ESPRC)</td>
<td>University of Lancaster</td>
</tr>
<tr>
<td>2-way collaborations</td>
<td>therapy developers</td>
</tr>
<tr>
<td>Consortium (commercial) funding</td>
<td>PAT consortium, &gt;20 international partners</td>
</tr>
</tbody>
</table>
Navigating application and award process: Practical tips and support for applicants

Chris Young
NCP for Legal and Financial Issues
Proposal submission and grant negotiations – practical considerations

Chris Young
Horizon Europe UK Legal and Financial National Contact Point

christopher.young@iuk.ukri.org
Proposal submission - general principles

- UK organisations – submit as a Beneficiary – candidate Associate Country
- Complete budget tables in full (Part A and Part B)
- Note eligibility requirements – multi-beneficiary topics – 1x MS + 2x MS/AC (consider + UK)
- Topic specific issues – participants, budget etc
- Consider NDA/MoU
Roles and responsibilities - general principles

- Organisations can participate in various roles: as coordinator, beneficiaries, affiliated entities, associated partners, in-kind contributors, subcontractors or recipients of financial support to third parties.

- Sufficient capacity must be demonstrated in the proposal and be available at the moment of the implementation of the work (i.e. not necessarily at the moment of submitting the proposal or signing the GA, but at least when the work starts).

- It is the beneficiaries that remain fully responsible towards the European Commission (the Commission) (they sign the Grant Agreement (GA)). For all the other consortium members, the obligations under the GA are indirect.
Roles and responsibilities – Coordinator v Beneficiary

- Beneficiaries are entities that sign the Grant Agreement

- The **coordinator** is the beneficiary who is the central contact point for the Commission and represents the consortium (towards the Commission) – they act as the “banker” for EU funds

- Ideally, the work should be done by the beneficiaries and their affiliated entities themselves, but if needed, they may involve other partners and rely on outside resources (*purchase new equipment, goods, works or services, subcontract a part of the work or involve associated partners, etc*).
Roles and responsibilities – Associated partners

- **Associated partners** – they implement action tasks but do not receive EU funding
- They do not sign the Grant Agreement but are actively involved in the consortium
- The Grant Agreement mentions them and defines their role but they are NOT beneficiaries
- The consortium is responsible for the implementation of the actions tasks by the Associated partner
- They do not have to account for their costs but applicants should include their costs in the budget of their proposal under other sources of finance, financial contributions and own resources headings
Roles and responsibilities – Subcontractor

- **Subcontracts** – these concern the implementation of "action tasks" as set out in Annex I of the Grant Agreement ie part of the project/project tasks that have been outsourced.
- The price for the subcontracts will be declared as subcontracting costs in the financial statement.
- Subcontractor’s motivation is financial, not the project itself and is paid by the beneficiary in exchange for its work.
- Subcontracting is limited and certain tasks are excluded (eg. Coordination)

*Example*: Subcontract to organise a conference that is set as part of the tasks in the description of the action.
Budget for the proposal

• The budget categories to be used for the call are set out in the call conditions and explained in the Annotated Model Grant Agreement https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf

• The budgeted costs should be based on a detailed and accurate estimation of your estimated project costs (based on the cost eligibility rules). They should include all your estimated costs.

• Cross-check Part A and Part B to see if you will also need to submit a detailed budget table or outline budgetary details in Part B.

• Keep your estimates on file — you may be required to produce them later on.

• Only the white cells need to be filled in (the grey cells are not applicable or automatically filled by the system).
### Part A - Budget for the proposal

#### 3 - Budget for the proposal

<table>
<thead>
<tr>
<th>No.</th>
<th>Participant</th>
<th>Country</th>
<th>Personal costs €</th>
<th>Subcontracting costs €</th>
<th>Purchase costs</th>
<th>Other costs categories</th>
<th>EU contribution to eligible costs</th>
<th>Estimated income</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Participant 1</td>
<td>NL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Participant 2</td>
<td>LR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Affiliated Entity</td>
<td>LR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Participant 3</td>
<td>DE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Associated Partner</td>
<td>AR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Part A - Budget for the proposal

<table>
<thead>
<tr>
<th>No</th>
<th>Participant name</th>
<th>Country</th>
<th>D.1</th>
<th>D.2</th>
<th>D.3</th>
<th>D.4</th>
<th>D.5</th>
<th>D.6</th>
<th>D.7</th>
<th>D.8</th>
<th>D.9</th>
<th>D.10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Financial support to third parties (Actual costs) (d1)</td>
<td>Internally invoiced goods and services (Unit costs - usual accounting practices) (d2)</td>
<td>Transnational access to research infrastructures (Unit costs) (d3)</td>
<td>Virtual access to research infrastructures (Unit costs) (d4)</td>
<td>CP/PR/PPR procurement costs (Actual costs) (d5)</td>
<td>Co-funded staff mobility costs (Unit costs) (d6)</td>
<td>Co-funded staff mobility costs (Actual costs) (d7)</td>
<td>Additional funding (subcontracts etc.) (Actual costs) (d8)</td>
<td>Additional funding (subcontracts etc.) (Actual costs) (d9)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Participant 1</td>
<td>NL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Participant 2</td>
<td>LB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Affiliated Entity</td>
<td>LB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Participant 3</td>
<td>DE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Associated Partner</td>
<td>AR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Successful evaluation – change of status (current position)

- On successful evaluation - coordinator receives letter from the Commission; three choices
  - Remove UK organisation (ineligible) and replace;
  - UK organisation changes status to Associated Partner;
  - Remove UK organisation and redistribute EU budget amongst existing beneficiaries

- Confirm participation as an Associated Partner - Letter of Intent (refer to guarantee)

- If threatened with removal:
  - inform PO; seek support (Consortium - ask for a vote)
  - Negotiate a lower budget
  - If NDA/MoU in place seek to enforce
  - Contact NCP
Standard European Commission text following successful evaluation

- Step 1 – identify new participant (minimum eligibility requirements)
- Step 2 – change to Associated Partner
- Step 2 (Alternative) – Existing beneficiaries plus new participant

Accordingly, your proposal will be declared ineligible and the Grant preparation terminated, unless you consider the steps suggested below.

To address the ineligibility of your proposal, I am inviting you to take the following possible actions so the Grant preparation of your proposal can continue:

**Step 1. Identification of new participant**

Identify a new participant(s) established in a Member State or an Associated Country not present in the original proposal to make sure that the proposal complies with the minimum eligibility conditions for participation. This new participant must take over some of the tasks (possibly including the tasks of the UK participants).

The redistribution of the budget and tasks will be accepted as non-substantial change unless these changes would put into question the results of the evaluation.

**Step 2. Change of status of the participant from beneficiary to associated partner**

Provided that the legal entities established in the United Kingdom are able to fund their tasks, their status may change from a beneficiary into an associated partner within the meaning of Article 9.1 of the Horizon Europe Model Grant Agreement. The total EU funding to the project will be reduced accordingly, except for tasks taken over by the new or existing eligible beneficiaries.

A redistribution of the remaining budget and tasks may be requested and should be accepted as non-substantial change unless it would put into question the results of the evaluation.

The entity may be later re-established as a beneficiary through a grant amendment if the association agreement with the United Kingdom becomes applicable and if requested by the consortium. If the association agreement provides for retroactive application prior to the start of the action and if the status changes to beneficiary, such conditions will apply.

**Alternative step 2: Withdrawal of the legal entities from participation in the proposal**

The tasks of the legal entities established in the United Kingdom are taken over either by the remaining other beneficiaries of the proposal, subject to the fulfillment of the minimum eligibility conditions for participation of the proposal, or by one or more additional new beneficiaries established in a Member State or an Associated Country. The legal entity established in the United Kingdom is withdrawn from the project. The total EU funding to the project may remain unchanged.
Associated partners - overview

UK organisations post successful evaluation – third country participant

DO NOT receive EU funding – self funding

DO NOT sign the Grant Agreement – NOT beneficiaries

CANNOT be a coordinator

DO NOT account for costs to EC - self funding/government guarantee

CAN be WP leaders, implement actions tasks – fully participate

Recognised role - Grant Agreement (Article 9.1) – role and tasks (Annex 1)
Associated partners and the Consortium Agreement

- Successful evaluation – UK participants convert to Associated Partners – third country participant (Note access rights on portal, no right to Grant Agreement)
- No direct right of EC to enforce - Consortium is responsible for the implementation of the actions tasks by the Associated partner
- Provisions from the Grant Agreement inserted in the Consortium Agreement – DESCA https://www.desca-agreement.eu/desca-model-consortium-agreement/
- Grant Agreement - Article 9.1
- Associated partners sign the Consortium Agreement – director or equivalent (not on the portal)
- Belgium law applies (insurance)
Consortium Agreement – Article 9.1

- Articles 9.1 lists the provisions that apply to Associated Partners as follows:
  - Article 11 (proper implementation)
  - Article 12 (conflict of interests)
  - Article 13 (confidentiality and security)
  - Article 14 (ethics)
  - Article 17.2 (visibility)
  - Article 18 (specific rules for carrying out action)
  - Article 19 (information)
  - Article 20 (record-keeping)
  - Article 25 (rights of various organisations).

- Above listed in the government guarantee p24/25
Associated partner/Consortium Agreement – current UK issues – practical considerations

- Proposal submission – Beneficiary - consider NDA/MoU or simple contract re ownership
- On successful evaluation - confirm participation - Letter of Intent (refer to guarantee)
- If threatened with removal:
  - inform PO; seek support (Consortium - ask for a vote)
  - Negotiate a lower budget
  - If NDA/MoU in place seek to enforce
  - Offer indemnity (shortfall in the budget)
  - Contact NCP
- Consortium Agreement – Limit any liability (total project costs), indemnity (only if pushed), right to the Grant Agreement (and amendments), carve out from financial provisions
Thank you
Key dates & Key Messages
Some Key dates for you

EU info days
https://research-and-innovation.ec.europa.eu/events/horizon-europe-info-days_en

• Health (Cluster 1): 19 January 2023
• Culture, Creativity and Inclusive Society (Cluster 2): 17 January 2023
• Digital, Industry and Space (Cluster 4) Info day – 12 - 14 December 2022
• Climate, Energy and Mobility (Cluster 5) Info day – 15 - 16 December 2022
• Food, Bioeconomy (Cluster 6) info day – 13 - 14 December 2022
• Research Infrastructures: 6 December 2022
• Marie Sklodowska-Curie: 7 December 2023 (Staff exchanges)
Horizon Europe Webinar Series

- 1 December 2022, 10am-12pm GMT – Cluster 5: Climate, Energy and Mobility
- 2 December 2022, 10am-12pm GMT – Cluster 1: Health
- 6 December 2022, 10-12pm GMT – Cluster 6: Food, Bioeconomy, Natural Resources, Agriculture and Environment
- 7 December 2022, 10am-12pm GMT – Cluster 2: Culture, Creativity and Inclusive Society
- 8 December 2022, 10am-12pm GMT – Cluster 4: Digital, Industry and Space
- 15 December 2022, 10am-12pm GMT – Cluster 3: Civil Security for Society

REGISTER HERE
“UK Horizon Europe Hub” https://ktn-uk.org/programme/european/
“…..It is our ambition to fully associate to both programmes if we can agree a fair and balanced deal, but we will make a final decision once it is clear whether such terms can be reached. If we are formally associated to Horizon Europe, the funding for UK participants will be allocated to the relevant UK organisations by the EU. In this scenario, if there were any gap before we became formally associated, we would implement short-term alternative funding arrangements through proven, attractive UK schemes. During any gap, we would provide funding to UK partners who are successful in bidding to programmes open to third country participation…..”